Benefits
Traditional 'female ginseng' use (limited modern RCT support)
Used in TCM for over 2,000 years for: dysmenorrhea, irregular menstruation, postpartum recovery, menopausal symptoms, blood deficiency, anemia, infertility. Considered the most important blood-tonifying herb in TCM women's health. Modern monotherapy RCTs have generally NOT confirmed efficacy for these claims — evidence base depends largely on traditional practice patterns and limited modern combination trials.
Negative for menopausal hot flashes (Hirata 1997 monotherapy)
Hirata 1997 (, Fertil Steril) double-blind placebo-controlled trial in 71 postmenopausal women showed dong quai monotherapy was NO MORE EFFECTIVE than placebo for menopausal vasomotor symptoms or vaginal cytology. NO estrogen-like effects observed. Foundational negative evidence for the most common Western marketing claim. Subsequent trials in androgen-deprivation hot flashes (Al-Bareeq 2010) also negative.
Possible benefit in COMBINATION TCM formulas (uncertain attribution)
Some trials of multi-herb TCM formulas containing dong quai (Dang Gui Bu Xue Tang, Xiao Yao San) show benefits for menopausal/menstrual symptoms — but cannot attribute effects specifically to dong quai. trial of dong quai + chamomile combination showed reduction in hot flashes. These data suggest dong quai may have efficacy in synergistic formulas rather than monotherapy.
Anti-platelet and circulation effects
Animal and in vitro studies show dong quai has modest antiplatelet activity (relevant to TCM 'blood-moving' concept) and improves microcirculation. Mechanism via ferulic acid and ligustilide. May contribute to traditional claims of postpartum recovery, dysmenorrhea relief, and cardiovascular support — but also creates bleeding risk concerns.
Mild estrogenic activity (in vitro)
In vitro studies show dong quai extracts have weak estrogen receptor binding — but the in vivo human relevance is unclear. Hirata 1997 specifically tested for estrogen-like effects (vaginal cytology, FSH, LH) and found NONE in monotherapy use. This contradicts the 'phytoestrogen' marketing positioning.
Mechanism of action
Antiplatelet activity via ferulic acid
Ferulic acid is a known antiplatelet compound — inhibits thromboxane A2 production and platelet aggregation. Mechanism for traditional 'blood-moving' classification. Also creates clinically relevant bleeding interaction with anticoagulants (warfarin INR elevation reported).
Vasodilation via ligustilide
Z-ligustilide is the primary essential oil component — produces smooth muscle relaxation and vasodilation in animal models. Relevant to traditional uses for circulation, dysmenorrhea (uterine relaxation), and headache. Mechanism distinct from estrogenic effects.
Mild phytoestrogen activity (limited in vivo relevance)
In vitro estrogen receptor binding observed but in vivo estrogen-like effects in humans NOT confirmed by Hirata 1997 RCT. The 'phytoestrogen' marketing for menopause is mechanistically weak when monotherapy is tested rigorously.
Anti-inflammatory effects
Multiple components inhibit COX-2 and reduce inflammatory cytokines in vitro and animal models. May contribute to traditional uses for pain (dysmenorrhea, arthralgia) — though clinical relevance for specific conditions unclear without rigorous trials.
Clinical trials
Randomized double-blind placebo-controlled trial (Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B 1997, Fertil Steril 68(6):981-986, doi:10.1016/s0015-0282(97)00397-x, PMID 9418683).
71 postmenopausal women with hot flashes randomized to 4.5 g/day dong quai (in capsules) or placebo for 24 weeks. Endpoints: Kupperman menopausal index, hot flash diary, vaginal cytology, FSH/LH levels.
PRIMARY ENDPOINTS NOT MET. NO significant differences between dong quai and placebo for vasomotor symptoms (hot flashes), Kupperman index, vaginal cells, or FSH/LH levels. NO estrogen-like activity demonstrated. Authors concluded: 'Used alone, dong quai does not produce estrogen-like responses in endometrial thickness or in vaginal maturation and was no more helpful than placebo in relieving menopausal symptoms.' Foundational pivotal negative trial that should temper menopause marketing claims.
Randomized double-blind placebo-controlled trial (Al-Bareeq RJ, Ray AA, Nott L, Pautler SE, Razvi H 2010, Can Urol Assoc J 4(1):49-53, doi:10.5489/cuaj.777, PMID 20165579).
22 men receiving LHRH agonist therapy for prostate cancer with bothersome hot flashes. Randomized 1:1 to daily placebo or dong quai for 3 months. Vasomotor and adverse events recorded daily; PSA, INR, PT/PTT measured at baseline and end.
NO significant differences in severity, frequency, or duration of hot flashes between dong quai and placebo groups. NO clinical bleeding problems during study despite theoretical concerns. Confirms negative finding in different population (men on ADT vs postmenopausal women). Limited by small pilot size but consistent with broader negative pattern in monotherapy trials.
Open-label clinical trial (Hudson 1998, Am J Nat Med).
55 women with menopausal symptoms received combination of dong quai + chamomile.
Dramatic reduction in hot flashes and night sweats reported. However, OPEN-LABEL design with NO placebo control — substantial bias risk. Cannot attribute effects to dong quai specifically (vs chamomile vs combination synergy vs placebo effect). Frequently cited but methodologically inferior to Hirata 1997 RCT. Illustrates the disconnect between traditional combination use and rigorous monotherapy testing.